Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Amyloidosis Is Often Underdiagnosed, Undertreated

Lara C. Pullen, PhD  |  Issue: July 2017  |  July 14, 2017

Nevertheless, amyloidosis “is still a missed diagnosis.” Dr. Libbey encouraged rheumatologists to add it to their list of differential diagnoses.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Causes of AA Amyloid

  • Inflammatory: rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, psoriatic arthritis, colitic arthropathy
  • Infectious: tuberculosis, osteomyelitis, leprosy, substance users/skin poppers, bronchiectasis
  • Autoinflammatory: familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome, cryopyrin-associated periodic syndrome, hyperimmunoglobulinemia D with periodic fever syndrome
  • Tumor: renal cell carcinoma, atrial myxoma, Hodgkins, IgG4 disease

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsResearch Rheum Tagged with:2017 State of the Art Clinical SymposiumAC&RAmerican College of Rheumatology (ACR)AmyloidosisDiagnosisinflammatory syndromepatient careResearchRheumatic DiseaserheumatologyTreatment

Related Articles

    What Rheumatologists Need to Know about Identifying Amyloidosis

    June 1, 2013

    Although amyloidosis is not a rheumatic disease, rheumatologists may be the first to diagnose this life-threatening condition

    The Legacy of Amyloid: Infiltration Linked to Dementia, Rheumatic Disease

    October 16, 2017

    An Unforgettable Story Her name was unforgettable. Not only did we share our given names—Simon and Simone, but her French-Canadian surname was based on this appellation, too. I was the junior resident working on our hospital’s nephrology service when she was admitted for evaluation of progressively worsening kidney disease and an overall failure to thrive….

    An Amylodosis Warning & New Drug Hope

    March 17, 2018

    SAN DIEGO—Treatments do exist that can improve the prospects of a patient with the rare disease amyloidosis, but only if clinicians keep the disease in mind and treat the patient before it’s too late, an expert said at the 2017 ACR/ARHP Annual Meeting this past November. He also discussed research that may be close to…

    2015 ACR/ARHP Annual Meeting: Treatments for Transthyretin-Related Amyloidosis Generate Interest from Researchers, Pharmaceuticals

    February 16, 2016

    SAN FRANCISCO—Treatment for transthyretin-related amyloidosis (ATTR) is generating more interest from academic researchers and the pharmaceutical industry, with encouraging early results using a multi-pronged therapeutic approach, a researcher said at a review course held before the 2015 ACR/ARHP Annual Meeting. Amyloidoses are a rare and potentially deadly family of diseases in which misfolded protein builds…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences